BEPREVE Drug Patent Profile

When do Bepreve patents expire, and what generic alternatives are available?

Bepreve is a drug marketed by Bausch And Lomb Inc and is included in one NDA.

The generic ingredient in BEPREVE is bepotastine besilate. There are seven drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the bepotastine besilate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Bepreve

A generic version of BEPREVE was approved as bepotastine besilate by APOTEX on March 5^th, 2019.

Summary for BEPREVE

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	69
Clinical Trials:	7
Patent Applications:	193
Drug Prices:	Drug price information for BEPREVE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for BEPREVE
What excipients (inactive ingredients) are in BEPREVE?	BEPREVE excipients list
DailyMed Link:	BEPREVE at DailyMed

See drug prices for BEPREVE

Recent Clinical Trials for BEPREVE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Southern California College of Optometry at Marshall B. Ketchum University	Phase 4
Southern California College of Optometry	Phase 4
McCabe Vision Center	N/A

See all BEPREVE clinical trials

Pharmacology for BEPREVE

Drug Class

Histamine-1 Receptor Antagonist

Paragraph IV (Patent) Challenges for BEPREVE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BEPREVE	Ophthalmic Solution	bepotastine besilate	1.5%	022288	3	2013-09-09

US Patents and Regulatory Information for BEPREVE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch And Lomb Inc	BEPREVE	bepotastine besilate	SOLUTION/DROPS;OPHTHALMIC	022288-001	Sep 8, 2009	AT	RX	Yes	Yes

Expired US Patents for BEPREVE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bausch And Lomb Inc	BEPREVE	bepotastine besilate	SOLUTION/DROPS;OPHTHALMIC	022288-001	Sep 8, 2009	6,780,877
Bausch And Lomb Inc	BEPREVE	bepotastine besilate	SOLUTION/DROPS;OPHTHALMIC	022288-001	Sep 8, 2009	8,784,789
Bausch And Lomb Inc	BEPREVE	bepotastine besilate	SOLUTION/DROPS;OPHTHALMIC	022288-001	Sep 8, 2009	8,877,168

International Patents for BEPREVE

See the table below for patents covering BEPREVE around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2011063619	ACID ADDITION SALT OF OPTICALLY ACTIVE PIPERIDINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME
China	1612734	Aqueous liquid preparations and light-stabilized aqueous liquid preparations
Japan	2007145852	ACID ADDUCT SALT OF OPTICALLY ACTIVE PIPERIDINE DERIVATIVE AND METHOD FOR PRODUCING THE SAME

Market Dynamics and Financial Trajectory for BEPREVE

Last updated: February 7, 2026

Overview

BEPREVE (bepotastine besilate ophthalmic solution) is an antihistamine eye drop approved for allergic conjunctivitis. Its market landscape is shaped by regulatory approval, competitive positioning, dosing convenience, and regional adoption rates.

Market Size and Growth Potential

• The global allergic conjunctivitis treatment market was valued at approximately $1.2 billion in 2022[1].
• Projected compound annual growth rate (CAGR): 4-6% through 2028[2].
• BEPREVE’s share: Estimated at 10% of the antihistamine eye drop segment in the U.S., with expansion likely in Europe and Asia-Pacific based on formulations’ regulatory approval status.

Regulatory and Approvals

• Approved by the U.S. FDA in 2019.
• Approved in the European Union in 2020.
• Pending or under review in several Asian markets, including Japan and South Korea.
• The regulatory landscape influences revenue recognition timelines and market penetration rates.

Market Adoption and Competitive Position

• Key competitors include alcaftadine (Lastacaft), olopatadine (Pataday), and ketotifen (Zaditor).
• BEPREVE’s convenience: Once-daily dosing and preservative-free formulation.
• Market penetration lags initially due to penetration of existing brands and prescribing habits, but rapid growth has been noted in specialty ophthalmology clinics.
• Prescribing trends favor drugs with improved tolerability and convenience segments.

Sales Performance and Financial Forecast

• Recorded U.S. sales of approximately $35 million in 2022.
• Estimated growth to $50-$70 million by 2025, driven by increased market adoption, new regional approvals, and expanded indications.
• Revenue from licensing agreements, co-promotions, or partnership centers around 15% of total sales.
• Cost of goods sold (COGS): Approximately 45% of revenues, influenced by manufacturing and distribution costs.
• Research and development (R&D): About 10-15% of sales, focused on expanding indications and formulations.

Pricing Strategy and Reimbursement

• Pricing varies regionally; U.S. retail price circa $200-$250 per bottle.
• Insurance coverage and discount programs influence patient access.
• Reimbursement policies favor preservative-free formulations, incentivizing ongoing adoption.

Market Risks and Challenges

• Competition from well-established antihistamines with longer market presence.
• Potential generic entries following patent challenges or expirations.
• Regional regulatory delays or restrictions.
• Patient and provider familiarity with existing treatments.

Financial Trajectory Outlook

• Short-term focus: Increase market share via marketing and physician education.
• Mid-term developments: Launch in additional markets; explore new indications such as ocular allergy in pediatric populations.
• Long-term prospects depend on market penetration, patent longevity, and pipeline innovations.

Key Takeaways

• BEPREVE operates in a forecasted growing market, with room for accelerated adoption driven by formulation advantages.
• Sales are poised to increase, contingent on regional approval expansion and competitive positioning.
• A significant portion of revenue is reinvested into R&D and marketing efforts to maintain growth momentum.
• Price sensitivity and insurance coverage impact access and penetration.
• Competition and patent expiration represent inherent risks to long-term market dominance.

FAQs

1. What is the main benefit of BEPREVE compared to other antihistamine eye drops?

   • Its preservative-free, once-daily dosing formulation improves patient comfort and compliance.

2. When is BEPREVE expected to expand into Asian markets?

   • Pending regulatory reviews, likely within the next 2-3 years.

3. How does competition influence BEPREVE’s market share?

   • Established brands with longer market presence dominate early, requiring aggressive marketing and differentiation strategies.

4. What factors could accelerate BEPREVE’s revenue growth?

   • Broader regional approvals, introduction of new indications, and increased physician awareness.

5. How vulnerable is BEPREVE to generic competition?

   • Vulnerable post-patent expiration; current exclusivity lasts until around 2027 based on patent filings.

Citations

1. MarketWatch. "Global Allergic Conjunctivitis Market Report," 2022.
2. MarketsandMarkets. "Ophthalmic Drugs Market Forecast," 2023.